Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NanoVir, LLC Receives $3M Preclinical Development NIAID Grant

Abstract:
The National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH), has awarded a nearly $3 million small Business Technology Transfer Research (STTR) grant to NanoVir, LLC to support synthesis and pre-clinical development of lead antiviral compounds for treatment of human papillomavirus 16 (HPV16).

NanoVir, LLC Receives $3M Preclinical Development NIAID Grant

Kalamazoo, MI | Posted on May 5th, 2010

The grant to NanoVir, which spans three years, will support work at several collaborating institutions including NanoVir, the University of Missouri-St. Louis and Stanford Research Institute-International.

HPV16 is by far the major cause of cervical dysplasia and cancer. Currently, no effective treatment for the virus is available or anticipated. Centers for Disease Control and the World Health Organization typically refer to "follow up" observation and surgical intervention as the only options available for women infected by HPV16. Their reports rarely even suggest that antivirals might soon provide hope for treatment.

The STTR grant from the NIAID will support preclinical development of antiviral compounds, discovered and designed by NanoVir scientists, which possess excellent potency for treatment of HPV16 in human cell culture. These compounds, which target the HPV origin of replication (ori), a DNA regulatory region within the HPV genome, were designed, synthesized and tested with the support of a previous NIAID-AT-STTR Phase 1 grant awarded to NanoVir by the NIAID. They hold considerable potential as antiviral agents that have the potential to add an important tool to complement the HPV vaccines and allow both HPV+ and HPV- patients to be treated.

"This Phase 2 award will allow us to initiate the chemical scale-up and safety studies required by the Food and Drug Administration before clinical trials can be initiated. We're honored to have been awarded this grant, especially at a time when the peer-review and competition for such awards is so stringent," said Chris Fisher, co-founder and Director of Biology of NanoVir. "This is a significant validation of our approach and I believe that, as long as we hit our milestones, we will soon be in a position to enter clinical trials in HPV-positive women."

NanoVir, LLC is a Michigan-based company whose headquarters are located at the Southwest Michigan Innovation Center in Kalamazoo, Michigan. NanoVir is working on prevention of cervical cancer by developing antiviral agents for HPV, the cause of the vast majority of cervical cancer. The company is funded by the National Institutes of Health, under the National Institute of Allergy and Infectious Diseases.

####

About NanoVir
NanoVir, LLC is a drug discovery company dedicated to finding treatments for HPV, a primary cause of both abnormal pap smears and cervical cancer. NanoVir focuses on studying DNA-targeted therapies aimed to treat high-risk HPV infection before it can progress to cancer. NanoVirís Kalamazoo site at the Southwest Michigan Innovation Center of Western Michigan University conducts cell-biology and virology studies, while its colleagues at the University of Missouri-St. Louis site carry out the related chemistry. The firm is currently concentrating on a topical treatment that could eliminate HPV infections.

About the Southwest Michigan Innovation Center
The Southwest Michigan Innovation Center is a 58,000-square-foot incubator/accelerator that provides wet-lab space, access to venture funding and comprehensive business support services to emerging companies in the life science industry. The Innovation Center is a state-of-the-art facility designed and staffed with high-tech scientific companies in mind. For more information, visit www.kazoosmic.com.

For more information, please click here

Contacts:
Send general inquires to:

Dr. Chris Fisher
NanoVir
4717 Campus Dr.
Kalamazoo, MI 49008
269.372.3261 office
269.372.3397 fax

Copyright © NanoVir

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Govt.-Legislation/Regulation/Funding/Policy

EC Project Aims at Creating and Commercializing Cyber-Physical-System Solutions November 14th, 2017

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3ís significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Leti Joins DARPA-Funded Project to Develop Implantable Device for Restoring Vision November 9th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Nanomedicine

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3ís significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

A new way to mix oil and water: Condensation-based method developed at MIT could create stable nanoscale emulsions November 8th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Announcements

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

Oxford Instruments announces winner of the 2017 Sir Martin Wood Prize for Japan November 14th, 2017

A new way to mix oil and water: Condensation-based method developed at MIT could create stable nanoscale emulsions November 8th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Nanobiotechnology

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3ís significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Age-old malaria treatment found to improve nanoparticle delivery to tumors: Nanomedicine researchers find new use for 70-year-old drug November 7th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project